转移性神经内分泌肿瘤的肽受体放射性核素治疗或依维莫司:SeqEveRIV研究,法国内分泌肿瘤研究组与Endocan-RENATEN网络的全国性研究
该回顾性多中心研究纳入84例接受依维莫司和肽受体放射性核素治疗(PRRT,177Lu-DOTATATE)的转移性神经内分泌肿瘤患者,比较两种治疗的疗效与安全性及两种序贯方案的总无进展生存期(PFS)。PRRT的客观缓解率和中位PFS均优于依维莫司且安全性更好,两种序贯方案的总PFS无显著差异。
要点
- PRRT的客观缓解率为22.6%(19例),依维莫司为6.0%(5例)。
- PRRT的中位PFS为24.5个月,依维莫司为16.1个月。
- 依维莫司-PRRT序贯与PRRT-依维莫司序贯的总PFS无显著差异(HR 0.69,P=0.22)。
核心结论
- PRRT比依维莫司更有效且毒性更低。
- 两种序贯方案的总PFS相似,若患者符合两种治疗条件建议个体化讨论,但当需要客观缓解或体弱人群时应首先使用PRRT。
研究设计与样本
- 回顾性多中心研究,纳入法国内分泌肿瘤研究组全国前瞻性数据库中2004年4月至2022年10月期间接受依维莫司和PRRT治疗的转移性神经内分泌肿瘤患者84例。
- 主要目的为比较依维莫司与PRRT的疗效和安全性,次要目的为基于总无进展生存期(PFS,第一治疗期间PFS+第二治疗期间PFS)评估两种序贯方案(PRRT后依维莫司或依维莫司后PRRT)。
主要发现
- 依维莫司的客观缓解率为6.0%(5例),中位PFS为16.1个月(95%CI 11.5-20.7个月)。
- PRRT的客观缓解率为22.6%(19例),中位PFS为24.5个月(95%CI 17.7-31.3个月)。
- PRRT的安全性也优于依维莫司。
- 依维莫司-PRRT序贯的中位总PFS为43.2个月(95%CI 33.7-52.7个月),PRRT-依维莫司序贯为30.6个月(95%CI 17.8-43.4个月)(HR 0.69;95%CI 0.39-1.24;P=0.22)。
临床怎么用
- PRRT比依维莫司更有效且毒性更低。
- 两种序贯方案的总PFS相似,若患者符合两种治疗条件建议个体化讨论,但当需要客观缓解或体弱人群时应首先使用PRRT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Everolimus and peptide receptor radionuclide therapy (PRRT, 177Lu-DOTATATE) are 2 treatments recommended in guidelines for gastroenteropancreatic metastatic neuroendocrine tumors. However, the best treatment sequence remains unknown. Methods: We designed a retrospective multicenter study that included patients from the national prospective database of the Groupe d'Étude des Tumeurs Endocrines who had been treated using everolimus and PRRT between April 2004 and October 2022. The primary aim was to compare the 2 treatments (everolimus and PRRT) in terms of efficacy and safety, and the secondary aim was to evaluate the sequences (PRRT followed by everolimus or everolimus followed by PRRT) based on overall progression-free survival (PFS) (PFS during first treatment + PFS during second treatment) in patients with metastatic neuroendocrine tumors. Results: Both treatments were used for 84 patients. The objective response rate and median PFS were 5 (6.0%) and 16.1 mo (95% CI, 11.5-20.7 mo), respectively, under everolimus and 19 (22.6%) and 24.5 mo (95% CI, 17.7-31.3 mo), respectively, for PRRT. The safety profile was also better for PRRT. Median overall PFS was 43.2 mo (95% CI, 33.7-52.7 mo) for the everolimus-PRRT sequence and 30.6 mo (95% CI, 17.8-43.4 mo) for the PRRT-everolimus sequence (hazard ratio, 0.69; 95% CI, 0.39-1.24; P = 0.22). Conclusion: PRRT was more effective and less toxic than everolimus. Overall PFS was similar between the 2 sequences, suggesting case-by-case discussion if the patient is eligible for both treatments, but PRRT should be used first when an objective response is needed or in frail populations.
引用
- Fosse A, Hadoux J, Girot P, et al. Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. J Nucl Med. 2024. PMID: 39089810. doi:10.2967/jnumed.123.267363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。